Cryolife Inc (NYSE:CRY) – Stock analysts at First Analysis issued their Q1 2020 EPS estimates for Cryolife in a report released on Wednesday, May 15th, according to Zacks Investment Research. First Analysis analyst anticipates that the medical equipment provider will earn $0.07 per share for the quarter.
Cryolife (NYSE:CRY) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, meeting the consensus estimate of $0.04. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The company had revenue of $67.50 million for the quarter, compared to analyst estimates of $66.37 million. During the same period in the prior year, the company posted $0.02 EPS. The company’s revenue was up 9.0% compared to the same quarter last year.
Several other equities research analysts have also weighed in on the company. TheStreet lowered Cryolife from a “b-” rating to a “c+” rating in a research note on Wednesday, May 22nd. ValuEngine lowered Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 15th. Needham & Company LLC reiterated a “hold” rating on shares of Cryolife in a research note on Sunday, May 12th. Canaccord Genuity reiterated a “buy” rating and issued a $35.00 price objective (up from $32.00) on shares of Cryolife in a research note on Wednesday, May 1st. Finally, Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research note on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Cryolife currently has a consensus rating of “Buy” and a consensus target price of $31.91.
Shares of CRY stock traded down $0.05 during trading hours on Friday, hitting $29.50. The company had a trading volume of 220,404 shares, compared to its average volume of 197,270. Cryolife has a 12 month low of $23.99 and a 12 month high of $36.05. The firm has a market cap of $1.10 billion, a P/E ratio of 113.31 and a beta of 0.61. The company has a current ratio of 4.90, a quick ratio of 3.69 and a debt-to-equity ratio of 0.86.
A number of institutional investors and hedge funds have recently made changes to their positions in CRY. Schonfeld Strategic Advisors LLC bought a new position in Cryolife in the 1st quarter valued at $7,086,000. Wasatch Advisors Inc. boosted its position in Cryolife by 50.9% in the 1st quarter. Wasatch Advisors Inc. now owns 498,176 shares of the medical equipment provider’s stock valued at $14,532,000 after buying an additional 168,125 shares during the last quarter. William Blair Investment Management LLC boosted its position in Cryolife by 41.5% in the 1st quarter. William Blair Investment Management LLC now owns 533,110 shares of the medical equipment provider’s stock valued at $15,551,000 after buying an additional 156,485 shares during the last quarter. BlackRock Inc. boosted its position in Cryolife by 2.8% in the 4th quarter. BlackRock Inc. now owns 5,533,113 shares of the medical equipment provider’s stock valued at $157,030,000 after buying an additional 152,026 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new position in Cryolife in the 1st quarter valued at $3,779,000. Hedge funds and other institutional investors own 71.20% of the company’s stock.
In related news, VP Scott B. Capps sold 2,000 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $28.55, for a total transaction of $57,100.00. Following the sale, the vice president now directly owns 141,079 shares in the company, valued at approximately $4,027,805.45. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Jean F. Holloway sold 8,654 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $32.00, for a total value of $276,928.00. Following the sale, the vice president now owns 67,020 shares in the company, valued at $2,144,640. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 99,609 shares of company stock worth $3,112,863. 4.40% of the stock is owned by corporate insiders.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.